Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

GHK-Cu

skinanti-aginghairhealing
Regulatory status — Research use only — not approved for human use

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex with mechanistic evidence supporting anti-inflammatory, antioxidant, and tissue-regenerative properties in animal models and cell culture systems. It is used in topical dermatological and hair care formulations, and is under investigation in preclinical models for applications ranging from wound healing to neurodegeneration. No randomized controlled trials in humans have been conducted for any indication, and all clinical efficacy claims remain preliminary.

Evidence coverage

30/34 claims verified by independent fact-checker.

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
—
Typical dose
See research context
Route
multiple
Frequency
[insufficient evidence in research packet]
Cycle length
—
Evidence strength
Animal models

Suggested labs for this peptide class — educational reference only; not medical advice.

TL;DR

  • Half-life: — — dosed —.
  • Administered via multiple.
  • Evidence base: animal model studies.
  • Primary goals: skin, anti-aging, hair, healing.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Primarily animal data

How we evaluate evidence →

How it works

BPC-157 acts on multiple parallel pathways — this multi-system action underlies its broad tissue repair profile.

GHK-Cu exerts its effects through several mechanistic pathways identified in animal and in vitro models. Animal studies in zebrafish larvae indicate anti-inflammatory activity against both CuSO₄- and LPS-induced inflammation [1]. Mechanistic data point to promotion of angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation in tissue repair contexts [3]. In vitro evidence indicates antioxidant properties in cell-based systems [2] [10]. Mechanistic data further suggest that GHK-Cu serves as a stable copper source that enhances lysyl oxidase (LOX) activation, a key enzyme in collagen crosslinking, in fascia regeneration models [11]. When applied topically, preliminary evidence suggests GHK-Cu may enhance collagen and glycosaminoglycan synthesis and support nerve outgrowth and angiogenesis [4]. In a murine model of ulcerative colitis, mechanistic data point to regulation via the SIRT1/STAT3 signaling pathway [8]. A mouse model of silicosis suggests GHK-Cu may attenuate lung inflammation and fibrosis by targeting peroxiredoxin 6 [9]. Notably, GHK-Cu has limited skin permeation due to its hydrophilic nature; mechanistic data indicate that liposomal encapsulation improves bioavailability in topical delivery contexts [7].

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Evidence awareness
  • Understand that all efficacy evidence for GHK-Cu is from animal models or cell culture; no human RCTs exist for any indication.
  • Recognize that human pharmacokinetics, dosing, and safety data are entirely absent from the published literature.
Medical consultation
  • Discuss use with a qualified clinician, particularly given the absence of human safety data.
  • Disclose any existing conditions or medications, as drug interaction data in humans do not exist.
Product quality
  • If using topical products, consider formulation quality and delivery system — liposomal encapsulation has been studied mechanistically for improved skin delivery [7].
  • Source compounds only from reputable suppliers with third-party testing, given the research-only status of GHK-Cu as a therapeutic agent.
  • No human clinical protocols have been established; there are no evidence-based preparation recommendations.
  • Consult a qualified clinician before use given the absence of human safety or dosing data.

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • No human trial-based monitoring parameters have been established.
  • Topical delivery via liposomal encapsulation has been suggested in mechanistic studies to improve bioavailability [7], but clinical benefit in humans has not been demonstrated.

After — Post-cycle

  • No evidence-based cycling or post-use guidance exists for GHK-Cu in humans.

Stacks it appears in

GHK-Cu is typically used as a standalone compound. Stack data coming soon.

Related peptides

Other compounds indexed on Pepteligence that share research tags with GHK-Cu. Educational context only.

Epitalon

Tier 3
anti-aging

BPC-157

Tier 3
healing

TB-500

Tier 3
healing

Sermorelin

Tier 3
anti-aging

Safety

Common side effects

  • ·[insufficient evidence in research packet — no human clinical trial data exist]

Rare side effects

  • ·[insufficient evidence in research packet — no human clinical trial data exist]
Safety notice — Serious / theoretical risks:
  • [insufficient evidence in research packet — no human clinical trial data exist]

Contraindications

  • ·No contraindications have been formally identified; absence of data does not imply safety.

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for GHK-Cu. Be the first to share yours.

Share your experience →

Have you tried GHK-Cu?

Share your protocol and outcome to help build the community dataset.

Share your experience →

GHK-Cu — at a glance

PropertyGHK-Cu—
Half-life——
Routemultiple—
Typical doseSee research context—
MechanismGHK-Cu exerts its effects through several mechanistic pathways identified in animal and in vitro models. Animal studies in zebrafish larvae indicate anti-inflammatory activity against both CuSO₄- and LPS-induced inflammation. Mechanistic data point to promotion of angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation in tissue repair contexts. In vitro evidence indicates antioxidant properties in cell-based systems. Mechanistic data further suggest that GHK-Cu serves as a stable copper source that enhances lysyl oxidase (LOX) activation, a key enzyme in collagen crosslinking, in fascia regeneration models. When applied topically, preliminary evidence suggests GHK-Cu may enhance collagen and glycosaminoglycan synthesis and support nerve outgrowth and angiogenesis. In a murine model of ulcerative colitis, mechanistic data point to regulation via the SIRT1/STAT3 signaling pathway. A mouse model of silicosis suggests GHK-Cu may attenuate lung inflammation and fibrosis by targeting peroxiredoxin 6. Notably, GHK-Cu has limited skin permeation due to its hydrophilic nature; mechanistic data indicate that liposomal encapsulation improves bioavailability in topical delivery contexts.—
Evidence strengthanimalanecdotal
Primary goalskin—

Frequently asked questions

What is GHK-Cu?
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex with mechanistic evidence supporting anti-inflammatory, antioxidant, and tissue-regenerative properties in animal models and cell culture systems. It is used in topical dermatological and hair care products and is classified as a research compound for systemic use.
How does GHK-Cu work?
Animal and in vitro studies indicate GHK-Cu promotes angiogenesis, supports integrin-mediated extracellular matrix remodeling, and activates fibroblasts. Animal studies in zebrafish larvae document anti-inflammatory activity against both CuSO₄- and LPS-induced inflammation. These pathways have not been validated in controlled human clinical trials for systemic use.
What is GHK-Cu used for?
GHK-Cu is commercially available in topical formulations for skin and hair applications. Animal and in vitro evidence for tissue-regenerative and anti-inflammatory properties has generated research interest in systemic use, but no clinical indications for systemic administration have been established in controlled human trials.
Is GHK-Cu FDA-approved?
GHK-Cu is not FDA-approved as a drug for any indication. It appears in topical cosmetic and dermatological formulations, but systemic therapeutic use has not been clinically validated or approved.
Is GHK-Cu naturally occurring in the body?
Yes. GHK-Cu is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Its natural occurrence at physiological concentrations distinguishes it from entirely synthetic research compounds, though research-context systemic use involves exogenous administration at doses distinct from endogenous concentrations.
How is GHK-Cu administered?
GHK-Cu has been studied via multiple routes in research settings. Topical application in cosmetic formulations is the established consumer use. No systemic route of administration has been validated for safety or efficacy in controlled human trials.
What are common side effects of GHK-Cu?
No controlled human clinical trial data exist to characterize the systemic side-effect profile of GHK-Cu. Its safety profile for systemic use is not established. Topical formulations are generally well-tolerated in consumer use.
Are there safety concerns with systemic GHK-Cu use?
No contraindications have been formally identified from human studies for systemic GHK-Cu use. The absence of human safety data means no definitive conclusions about safety in any clinical population can be drawn. Absence of data does not imply safety.
Is GHK-Cu the same as copper peptides in skincare?
GHK-Cu is the specific tripeptide-copper complex used in many "copper peptide" skincare products. The tripeptide (GHK) binds copper ions to form this complex, which is incorporated into topical formulations. The research evidence for topical effects is separate from and distinct from systemic use as a research compound.
Can GHK-Cu be combined with other compounds?
No evidence-supported combination protocols have been established for systemic GHK-Cu use. The current source literature does not document any stacking combinations with human-validated data.
Is GHK-Cu legal?
GHK-Cu is not a scheduled controlled substance in the United States and is commercially available in topical cosmetic products. Its legal status for systemic use as a therapeutic or research compound varies by jurisdiction. This is not legal advice.
What does the research on GHK-Cu show overall?
GHK-Cu's research base consists of animal models and cell culture experiments. It is a naturally occurring tripeptide-copper complex with promising mechanistic signals in preclinical research, particularly for anti-inflammatory and tissue-regenerative properties. Controlled human trials validating systemic efficacy or safety have not been conducted.

References

  1. [1]

    Glycyl-L-histidyl-L-lysine-Cu2+ (GHK-Cu) Attenuates CuSO4 or LPS induced-inflammation in Zebrafish larvae model.

    Hu Jing, Zhang Chao, Wang Feifei

    European journal of pharmacology · 2026 · PMID 41997403

  2. [2]

    Copper Complexes with New Glycyl-l-histidyl-l-lysine-Hyaluronan Conjugates Show Antioxidant Properties and Osteogenic and Angiogenic Synergistic Effects.

    Greco Valentina, Lanza Valeria, Tomasello Barbara et al.

    Bioconjugate chemistry · 2025 · PMID 40123442

  3. [3]

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    Rahman Omar F, Lee Steven J, Seeds William A

    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 · PMID 41490200

  4. [4]

    Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.

    Mortazavi Seyedeh Maryam, Mohammadi Vadoud Seyyed Ali, Moghimi Hamid Reza

    BioImpacts : BI · 2025 · PMID 39963574

  5. [5]

    Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application.

    Liu Tianqi, Liu Ying, Zhao Xiaoyu et al.

    Bioactive materials · 2024 · PMID 38026438

  6. [6]

    Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.

    Tucker Matthew, Liao Gerald Yu, Keely Addison et al.

    Aging pathobiology and therapeutics · 2024 · PMID 40766919

  7. [7]

    Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?

    Ogórek Karolina, Nowak Kinga, Wadych Emilia et al.

    Molecules (Basel, Switzerland) · 2025 · PMID 39795193

  8. [8]

    Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.

    Mao Shuzhen, Huang Jiahui, Li Junyan et al.

    Frontiers in pharmacology · 2025 · PMID 40672369

  9. [9]

    The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.

    Bian Yiding, Deng Mingming, Liu Jia et al.

    Redox biology · 2024 · PMID 38879894

  10. [10]

    An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant.

    Hu Die, Zhang Xuexun, Gong Shiwen et al.

    Colloids and surfaces. B, Biointerfaces · 2025 · PMID 40716276

  11. [11]

    Golgi-targeted copper delivery strategy via enhancing copper-dependent proteins' activity for fascia regeneration.

    Wang Rui, Xu Yiru, Saiding Qimanguli et al.

    Journal of controlled release : official journal of the Controlled Release Society · 2026 · PMID 41371501

  12. [?]

    Palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in both A375 and B16 cell lines.

    Hong Minhua, Gui Yingyue, Xu Jiayao et al.

    Biochemical and biophysical research communications · 2025 · PMID 39632290